Erectile Dysfunction Market Size, Share, Growth Analysis, By Product(Viagra, Cialis, Zydena, Levitra), By Region - Industry Forecast 2024-2031

Report ID: SQSG35I2033 | Region: Global | Published Date: July, 2036
Pages: 165 | Tables: 39 | Figures: 73

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Analyst Support


Erectile Dysfunction Market size was valued at USD 2.3 billion in 2019 and is poised to grow from USD 2.49 billion in 2023 to USD 4.73 billion by 2031, growing at a CAGR of 8.5% in the forecast period (2024-2031).

Key market participants in the erectile dysfunction (ED) drugs market are strengthening their market positions by implementing a variety of strategies, including mergers and acquisitions and research partnerships with other businesses, to introduce novel products and solidify their market positions globally. For instance, due to a production error, Sun Pharmaceutical Industries Ltd. announced the recall of their generic medicine Tadalafil in November 2021. A small gap in the availability of generic ED medications used to treat erectile dysfunction patients may result from this recall. 'Pfizer Inc.', 'Eli Lilly and Company', 'Bayer AG', 'VIVUS, Inc.', 'Dong-A ST Co. Ltd.', 'Meda Pharmaceuticals Inc.', 'S.K. Chemicals Co. Ltd.', 'Teva Pharmaceutical Industries Ltd.', 'Endo International plc', 'Futura Medical plc', 'Apricus Biosciences, Inc.', 'Medtronic plc', 'Coloplast Corp.', 'Boston Scientific Corporation', 'Zephyr Surgical Implants', 'Urologix, LLC', 'American Medical Systems, Inc.', 'Augusta Medical Systems, LLC', 'Pos-T-Vac Medical'

Diabetes, obesity, and cardiovascular disease are on the rise due to the rise in the adoption of an unhealthy lifestyle, which in turn causes issues like ED as people age. Young people's current lifestyles are particularly stressful in many emerging nations, which has led to an increase in fast food and ready-to-eat food consumption as well as drinking and smoking. These variables are compromising general health and fitness, which in turn raises the risk of ED. Additionally, the number of ED patients increases along with the senior population growth, which continues to be a major driver of the worldwide erectile dysfunction medications market during the projection period.

The medication sildenafil is used to treat erectile dysfunction. By boosting blood flow to the penis, it aids males in obtaining an erection. At least two-thirds of the men who took it said their erections got better. The drug sildenafil is used to treat pulmonary arterial hypertension and erectile dysfunction, among other conditions. It is marketed under the trade name Viagra among others. Its efficacy in treating female sexual dysfunction has not been shown. The most popular medication used as initial therapy for erectile dysfunction is sildenafil (Viagra). So, throughout the projection period, the segment is anticipated to grow due to the success of Viagra (sildenafil citrate) in the treatment of erectile dysfunction.

The erectile dysfunction industry is expected to be dominated by North America. The prevalence of erectile dysfunction, the well-developed healthcare system, and the accessibility of treatment tools are all factors in the supremacy.

Feedback From Our Clients

Global Erectile Dysfunction Market

Product ID: SQSG35I2033